Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 8/20 | 0.42 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760243 | 0.86 | HDAC2 (0.43) | HDAC2HDAC1WDR5MAPTTHRB | |
| SCHEMBL1705492 | 0.76 | HDAC1 (0.51) | HDAC2KCNQ4KCNQ5HDAC1WDR5 | |
| SCHEMBL1705996 | 0.75 | HDAC2 (0.37) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3766947 | 0.73 | LTB4R2 (0.35) | HDAC2KCNQ4KCNQ5HDAC1PTPN1 | |
| SCHEMBL651937 | 0.71 | HDAC1 (0.49) | HDAC2HDAC1HDAC3 | |
| SCHEMBL23155538 | 0.67 | ACHE (0.39) | — | |
| SCHEMBL29812125 | 0.67 | ACHE (0.39) | — | |
| SCHEMBL29811918 | 0.67 | MAPK1 (0.46) | KCNQ4KCNQ5 | |
| SCHEMBL23143701 | 0.67 | MAPK1 (0.46) | KCNQ4KCNQ5 | |
| SCHEMBL30091846 | 0.67 | HDAC1 (0.56) | HDAC2KCNQ4KCNQ5HDAC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8258316-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | HDAC2 5/4885KCNQ4 3579/4885KCNQ5 2888/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | HDAC2 5/4885KCNQ4 3579/4885KCNQ5 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.